CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key Findings of the Study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Market dynamics

3.3.1.Drivers

3.3.1.1.Rise in need for preventing unwanted pregnancy
3.3.1.2.Increasing awareness for contraceptives worldwide
3.3.1.3.Rising usage of oral contraceptives as a preferred method to avoid unplanned pregnancy
3.3.1.4.Upsurge in government and NGO initiatives promoting contraceptives
3.3.1.5.Increasing awareness about STDs

3.3.2.Restraints

3.3.2.1.Health risks associated with the use of contraceptive methods
3.3.2.2.Lack of social acceptance

3.3.3.Opportunity

3.3.3.1.Rise in disposable income and demand for healthy life in emerging economies
3.3.3.2.Presence of large unmet contraceptive needs in emerging asian and african economies

3.4.COVID Impact on the market

CHAPTER 4:CONTRACEPTIVE DRUGS MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Oral contraceptive pills

4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country

4.3.Injectable contraceptives

4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Topical contraceptives

4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:CONTRACEPTIVE DRUGS MARKET, BY AGE GROUP

5.1.Overview

5.1.1.Market size and forecast

5.2.15-24 years

5.2.1.Market size and forecast
5.2.2.Market analysis, by country

5.3.25-34 years

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

5.4.35-44 years

5.4.1.Market size and forecast
5.4.2.Market analysis, by country

5.5.Above 44 years

5.5.1.Market size and forecast
5.5.2.Market analysis, by country

CHAPTER 6:CONTRACEPTIVE DRUGS MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Homecare

6.2.1.Market size and forecast
6.2.2.Market analysis, by country

6.3.Hospitals

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Clinics

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

CHAPTER 7:CONTRACEPTIVE DRUGS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by country
7.2.3.North America contraceptive drugs market by product
7.2.4.North America contraceptive drugs market by age group
7.2.5.North America contraceptive drugs market by end user
7.2.6.U.S.

7.2.6.1.U.S. contraceptive drugs market by product
7.2.6.2.U.S. contraceptive drugs market by age group
7.2.6.3.U.S. contraceptive drugs market by end user

7.2.7.Canada

7.2.7.1.Canada contraceptive drugs market by product
7.2.7.2.Canada contraceptive drugs market by age group
7.2.7.3.Canada contraceptive drugs market by end user

7.2.8.Mexico

7.2.8.1.Mexico contraceptive drugs market by product
7.2.8.2.Mexico contraceptive drugs market by age group
7.2.8.3.Mexico contraceptive drugs market by end user

7.3.Europe

7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Europe contraceptive drugs market by product
7.3.4.Europe contraceptive drugs market by age group
7.3.5.Europe contraceptive drugs market by end user
7.3.6.Germany

7.3.6.1.Germany contraceptive drugs market by product
7.3.6.2.Germany contraceptive drugs market by age group
7.3.6.3.Germany contraceptive drugs market by end user

7.3.7.France

7.3.7.1.France contraceptive drugs market by product
7.3.7.2.France contraceptive drugs market by age group
7.3.7.3.France contraceptive drugs market by end user

7.3.8.UK

7.3.8.1.UK contraceptive drugs market by product
7.3.8.2.UK contraceptive drugs market by age group
7.3.8.3.UK contraceptive drugs market by end user

7.3.9.Rest of Europe

7.3.9.1.Rest of Europe contraceptive drugs market by product
7.3.9.2.Rest of Europe contraceptive drugs market by age group
7.3.9.3.Rest of Europe contraceptive drugs market by end user

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Asia-Pacific contraceptive drugs market by product
7.4.4.Asia-Pacific contraceptive drugs market by age group
7.4.5.Asia-Pacific contraceptive drugs market by end user
7.4.6.Japan

7.4.6.1.Japan contraceptive drugs market by product
7.4.6.2.Japan contraceptive drugs market by age group
7.4.6.3.Japan contraceptive drugs market by end user

7.4.7.China

7.4.7.1.China contraceptive drugs market by product
7.4.7.2.China contraceptive drugs market by age group
7.4.7.3.China contraceptive drugs market by end user

7.4.8.Australia

7.4.8.1.Australia contraceptive drugs market by product
7.4.8.2.Australia contraceptive drugs market by age group
7.4.8.3.Australia contraceptive drugs market by end user

7.4.9.India

7.4.9.1.India contraceptive drugs market by product
7.4.9.2.India contraceptive drugs market by age group
7.4.9.3.India contraceptive drugs market by end user

7.4.10.Rest of Asia-Pacific

7.4.10.1.Rest of Asia-Pacific contraceptive drugs market by product
7.4.10.2.Rest of Asia-Pacific contraceptive drugs market by age group
7.4.10.3.Rest of Asia-Pacific contraceptive drugs market by end user

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by country
7.5.3.LAMEA contraceptive drugs market by product
7.5.4.LAMEA contraceptive drugs market by age group
7.5.5.LAMEA contraceptive drugs market by end user
7.5.6.Brazil

7.5.6.1.Brazil contraceptive drugs market by product
7.5.6.2.Brazil contraceptive drugs market by age group
7.5.6.3.Brazil contraceptive drugs market by end user

7.5.7.Saudi Arabia

7.5.7.1.Saudi Arabia contraceptive drugs market by product
7.5.7.2.Saudi Arabia contraceptive drugs market by age group
7.5.7.3.Saudi Arabia contraceptive drugs market by end user

7.5.8.South Africa

7.5.8.1.South Africa contraceptive drugs market by product
7.5.8.2.South Africa contraceptive drugs market by age group
7.5.8.3.South Africa contraceptive drugs market by end user

7.5.9.Rest of LAMEA

7.5.9.1.Rest of LAMEA contraceptive drugs market by product
7.5.9.2.Rest of LAMEA contraceptive drugs market by age group
7.5.9.3.Rest of LAMEA contraceptive drugs market by end user

CHAPTER 8:COMPANY PROFILES

8.1.Agile Therapeutics

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Business performance

8.2.Allergan Plc.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Business performance

8.3.Bayer AG

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Business performance

8.4.GlaxoSmithKline Plc

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Business performance
8.4.5.Key strategic moves and developments

8.5.Johnson & Johnson

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Business performance
8.5.5.Key strategic moves and developments

8.6.Piramal Healthcare

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Business performance

8.7.Mylan N.V.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Business performance

8.8.Pfizer Inc.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Business performance
8.8.5.Key strategic moves and developments

8.9.Novartis AG

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Business performance
8.9.5.Key strategic moves and developments

8.10.Teva Pharmaceutical Industries Ltd.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Business performance
8.10.5.Key strategic moves and developments